Since the outbreak of the novel COVID-19 virus, we have been extremely busy with the implementation of the necessary precautions to be able to provide treatments for the millions of people relying on us. We are following the recommendations from the governments, and only a minimal number of employees are working on-site to maintain our ability to keep our labs running and produce and deliver medicines all over the world. The Lundbeck supply chain remains intact, and we have not experienced any supply disruptions. We are closely monitoring the integrity of the entire supply chain, and we are committed to doing all we can to anticipate and mitigate any potential issues with the availability of our therapies.
We have initiated our contingency plans to continue clinical trials safely, and we are maintaining effective patient reporting processes, ensuring the safety of our patients. Delivering the required treatments to people living with brain diseases while keeping our employees safe will remain our top priority, and we hope that we, together with the rest of the world, can come swiftly through this.
As a global company, we are collaborating with authorities, patient groups and other relevant stakeholders in different countries around the world - and we are doing our utmost to support local communities and societies such as monetary and medicine donations to Wuhan, fundraising activities in Italy, donations of protective equipment in France and in the US, together with support for local patient organizations.
We are furthermore proud to be part of the Lundbeck Foundation family with the Lundbeck Foundation at the forefront of supporting science to be able to prevent, treat and ultimately stop the coronavirus.
We will continue to support in any way we can where ever we can.